UN chief Guterres pushes drug firms to voluntary share COVID-19 vaccine licenses
UN chief Antonio Guterres believes vaccine makers should allow other companies to produce versions of their COVID-19 shots, a UN spokesman said on Wednesday, as the World Trade Organization discussed waiving patent rights to boost supply to developing countries.
“The Secretary-General has often called for technology transfers and sharing of know-how and voluntary licensing or sharing of licensing,” spokesman Stephane Dujarric said.
For more coronavirus news, visit our dedicated page.
WTO members are assessing signs of progress after seven months of talks on a proposal by South Africa and India to waive patent rights on COVID-19 vaccines. WTO decisions are based on consensus, so all 164 members must agree.
For the latest headlines, follow our Google News channel online or via the app.
Some UN officials say the waiver discussion is a distraction and an ideological fight that won’t solve the problem of how to scale up vaccine manufacturing.
The 60 sponsors of the proposal from emerging economies are pitted against richer developed countries -- such as Switzerland, the United States and in the European Union -- where many pharmaceutical companies are based.
Guterres has long called for COVID-19 vaccines to be made available to all countries and appealed for more money to fund the COVAX vaccine sharing facility, which aims to buy up to 1.8 billion doses in 2021 to ensure equitable global access.
COVAX is run by the Gavi Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization (WHO) and the UN children’s agency UNICEF.
Last month UNICEF called for vaccine Intellectual Property Rights (IPR) to be simplified through “voluntary and proactive licensing” but warned this alone wouldn’t increase production.
“IPR holders would need to provide technology partnerships to accompany IP licenses, proactively share know-how and sub-contract to manufacturers without undue geographic or volume restrictions,” UNICEF Executive Director Henrietta Fore said.
“This challenge requires not forced IP waivers but proactive partnership and cooperation,” she said.
She cited recent manufacturing partnerships as “encouraging examples” and urged others to follow suit, to increase the scale and geographic diversity of manufacturing capacity.
WHO chief denounces vaccine inequity as COVAX sharing scheme marks first year
India to help fund capacity boost at Serum Institute as vaccines run low
Canada approves use of Pfizer vaccine for kids aged 12 and above
Coronavirus: Vaccine giant to apply for pandemic license in ‘two weeks’The world’s largest vaccine manufacturer by volume said Saturday it would apply for an emergency license for a coronavirus vaccine within two weeks, ... Coronavirus
UN program to provide 500 mln Moderna vaccine doses starting Q4Moderna and vaccine promoter Gavi have announced a firm deal by which the pharmaceutical company will provide up to 500 million doses for the ... Coronavirus
Italy achieves daily COVID-19 immunization target despite slow vaccine deliveriesItaly has hit its target of administering 500,000 COVID-19 vaccinations in a single day, Health Minister Roberto Speranza said on Friday. ... Coronavirus
UK study underscores need for second Pfizer COVID-19 vaccine dosePeople who haven’t fought off Covid-19 before are still vulnerable to infection from variants after getting the first dose of Pfizer Inc. and BioNTech ... Coronavirus
WHO chief denounces vaccine inequity as COVAX sharing scheme marks first yearCoronavirus vaccines remain out of reach in the poorest countries, the head of the World Health Organization (WHO) said in a report on Friday, marking ... Coronavirus
UNICEF says problem of delays in AstraZeneca vaccine supplies outside India resolvedProblems that have delayed AstraZeneca supplies to the COVAX vaccine-sharing facility have been resolved, UNICEF told Reuters on Tuesday, saying it ... Coronavirus
India to help fund capacity boost at Serum Institute as vaccines run lowIndia is set to accept the Serum Institute of India’s (SII) request for a grant of 30 billion rupees ($400 million) to boost its capacity to make the ... Coronavirus